Goode, E.L., Block, M.S., Kalli, K.R., Vierkant, R.A., Chen, W., Fogarty, Z.C., Gentry-Maharaj, A., Toloczko, A., Hein, A., Bouligny, A.L., Jensen, A., Osorio, A., Hartkopf, A., Ryan, A., Chudecka-Glaz, A., Magliocco, A.M., Hartmann, A., Jung, A.Y., Gao, B., Hernandez, B.Y., Fridley, B.L., McCauley, B.M., Kennedy, C.J., Wang, C., Karpinskyj, C., De Sousa, C.B., Tiezzi, D.G., Wachter, D.L., Herpel, E., Taran, F.A., Modugno, F., Nelson, G., Lubiński, J., Menkiszak, J., Alsop, J., Lester, J., García-Donas, J., Nation, J., Hung, J., Palacios, J., Rothstein, J.H., Kelley, J.L., De Andrade, J.M., Robles-Díaz, L., Intermaggio, M.P., Widschwendter, M., Beckmann, M.W., Ruebner, M., Jimenez-Linan, M., Singh, N., Oszurek, O., Harnett, P.R., Rambau, P.F., Sinn, P., Wagner, P., Ghatage, P., Sharma, R., Edwards, R.P., Ness, R.B., Orsulic, S., Brucker, S.Y., Johnatty, S.E., Longacre, T.A., Ursula, E., McGuire, V., Sieh, W., Natanzon, Y., Li, Z., Whittemore, A.S., Anna, deFazio; Staebler, A., Karlan, B.Y., Gilks, B., Bowtell, D.D., Hogdall, E., Candido Dos Reis, F.J., Steed, H., Campbell, I.G., Gronwald, J., Benítez, J., Koziak, J.M., Chang-Claude, J., Moysich, K.B., Kelemen, L.E., Cook, L.S., Goodman, M.T., García, M.J., Fasching, P.A., Kommoss, S., Deen, S., Kjaer, S.K., Menon, U., Brenton, J.D., Pharoah, P.D., Chenevix-Trench, G., Huntsman, D.G., Winham, S.J., Kobel, M. and Ramus, S.J. (2017) Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology, 3, e173290.
https://doi.org/10.1001/jamaoncol.2017.3290

has been cited by the following article:

• TITLE: Multiple Potential Markers of Chemosensitivity of Ovarian Cancer, Among Which KELIM of CA125 Is Low Cost and Efficient

  AUTHORS: Huilin Tu, Zhe Wang, Luya Cai, Xiaoxu Zhu, Jianhua Qian

  KEYWORDS: Epithelial Cancer of the Ovary, Chemotherapy in GYN Cancers

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.2, February 23, 2024

  ABSTRACT: Aim: Ovarian cancer (OC) is a malignant cancer with the highest death rate among various kinds of gynecological tumors. The treatment pattern of HGSCs is mainly primary debulking surgery (PDS), followed by platinum-based adjuvant chemotherapy, which has been the preferred treatment plan in recent years. Treatment decision-making remains a problem that needs to be addressed. We write this article to summarize the relevant indicators reported and find better decision-making tools. Methods: We have extensively read and understood the literature in the research field involved. We searched for keywords in Pubmed: ovarian cancer; KELIM; chemosensitivity. Later we summarized and organized the current research status in the last two decades. Results: There are many predictors of chemotherapy sensitivity, including pathological chemotherapy response score (CRS), the level of tumor-infiltrating lymphocytes (TILs), BRCA mutations in germ lines or somatic cells, tumor homologous recombination deficiency (HRD), KELIM of CA125 and so on. Many clinical trials have testified that this marker of chemosensitivity all have their own advantages and disadvantages. KELIM of CA125 is low-cost and efficient, which is worth promoting and applying in clinical practice. Conclusions: Many studies have validated the predictive and guiding value of the KELIM of Ca125 in the diagnosis and therapy of ovarian cancer. Nowadays, KELIM of Ca125 is rarely known by clinical doctors and lacks clinical application. We advise that KELIM of CA125 is a potential prognostic factor of ovarian cancer. As a clinical doctor in the process of treating ovarian cancer, we can combine the patient’s situation with KELIM, to develop personalized treatment plans. Not only can it reduce the occurrence of complications, but it can also lower medical costs.